[Skip to Content]
[Skip to Content Landing]
Views 853
Citations 0
Viewpoint
April 27, 2020

Affording Genetic Therapies in the Medicaid Program

Author Affiliations
  • 1Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
  • 2Johns Hopkins Drug Access and Affordability Initiative, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
JAMA Pediatr. 2020;174(6):523-524. doi:10.1001/jamapediatrics.2020.0168

Therapies that insert genes, inactivate malfunctioning genes, or alter gene expression have marked therapeutic potential for diseases of childhood. Two recently approved treatments for infantile-onset spinal muscular atrophy type 1 (SMA), which was previously uniformly fatal in early childhood, can increase survival among children. Potentially transformative genetic therapies are in the pipeline for Duchenne muscular dystrophy, sickle cell disease, and cystic fibrosis, among other conditions.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×